HC Wainwright Has Optimistic Outlook of RARE Q1 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($1.55) per share for the quarter, up from their prior estimate of ($1.63). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($4.05) EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $1.19 EPS, Q3 2027 earnings at $1.55 EPS, Q4 2027 earnings at $2.64 EPS and FY2027 earnings at $5.66 EPS.

RARE has been the topic of a number of other reports. Leerink Partners cut their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Wells Fargo & Company cut their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday, December 30th. Jefferies Financial Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, December 30th. Guggenheim dropped their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Finally, Barclays reduced their target price on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th. Sixteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $68.29.

Ultragenyx Pharmaceutical Trading Up 1.3%

Shares of Ultragenyx Pharmaceutical stock opened at $20.45 on Thursday. The company has a market capitalization of $1.97 billion, a P/E ratio of -3.50 and a beta of 0.16. The stock has a fifty day simple moving average of $25.96 and a 200 day simple moving average of $29.60. Ultragenyx Pharmaceutical has a 12-month low of $18.41 and a 12-month high of $45.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The company had revenue of $207.28 million during the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.The business’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same period last year, the company earned ($1.39) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in RARE. Jacobs Levy Equity Management Inc. boosted its position in Ultragenyx Pharmaceutical by 614.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock worth $65,205,000 after purchasing an additional 1,864,164 shares during the period. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $29,004,000. Millennium Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 787.6% during the 4th quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company’s stock valued at $20,255,000 after buying an additional 781,431 shares in the last quarter. Vestal Point Capital LP bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $22,560,000. Finally, Russell Investments Group Ltd. boosted its holdings in Ultragenyx Pharmaceutical by 599.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 840,451 shares of the biopharmaceutical company’s stock worth $25,281,000 after buying an additional 720,256 shares during the period. Institutional investors own 97.67% of the company’s stock.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,061 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the transaction, the chief financial officer directly owned 88,935 shares of the company’s stock, valued at approximately $2,095,308.60. This represents a 3.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 6,227 shares of company stock valued at $187,126. Insiders own 5.50% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Canaccord lowered its price target to $79 from $128 but maintained a “buy” rating, citing continued upside potential (the new PT implies large upside versus current levels). Canaccord PT Cut
• Positive Sentiment: HC Wainwright cut its target to $50 (from $60) while keeping a “buy” rating, signaling broker confidence in longer‑term value despite lowering near‑term expectations. HC Wainwright Coverage
• Neutral Sentiment: Wedbush reaffirmed a “neutral” rating with a $25 price target, reflecting a more cautious near‑term view and limited upside relative to the current price. Wedbush Note
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Levi & Korsinsky, Robbins LLP, Berger Montague, Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, The Gross Law Firm, Kahn Swick & Foti, Schall Law Firm and others) have filed or are soliciting investors to join a securities‑class action covering purchases from Aug 3, 2023 to Dec 26, 2025 and are urging appointment of a lead plaintiff by April 6, 2026 — this creates legal and financial uncertainty (potential discovery, defense costs, settlement risk). Representative notices: Gross Law Firm Notice Levi & Korsinsky Notice Rosen Law Firm Notice

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.